Actelion, a part of the Johnson & Johnson Family of Companies, is a global leader in the treatment of pulmonary arterial hypertension (PAH), a serious condition affecting the pulmonary arteries and the right side of the heart. The company specializes in developing and commercializing innovative medicines that address the complex pathways and molecular mechanisms of PAH, thereby improving patient outcomes. Actelion also offers treatments for other serious illnesses, including type 1 Gaucher disease, Niemann-Pick type C disease, and digital ulcers in patients with systemic sclerosis.

Actelion operates in the pharmaceutical industry, serving patients worldwide who suffer from these severe conditions. The company’s business model focuses on research and development, leveraging its scientific expertise to bring new and effective treatments to market. Revenue is generated through the sale of its specialized medicines, which are distributed globally.

As a leader in PAH, Actelion continues to expand its geographic and commercial reach, aiming to bring its in-market medicines to more patients around the world. The company is also accelerating market entry for its promising late-stage development assets, ensuring a steady pipeline of innovative treatments.

Keywords: pulmonary arterial hypertension, PAH, innovative medicines, Gaucher disease, Niemann-Pick type C, digital ulcers, systemic sclerosis, Johnson & Johnson, global leader, patient outcomes.